No, not even close, SRX had a big Court case outcome looming over it from the beginning which they won against UWA & Dr Bruce Gray. The precedent created means that SRX (& its SP) have had a beneficial springboard in liver cancer space ever since. Please find attached an open source review with original Full Federal Court link (High Court refused leave to appeal): www.austlii.edu.au/au/cases/cth/FCAFC/2009/116.html:
The IP case hung over SRX from its IPO & subdued SRX's SP pending outcome. Employment contracts were never ever the same in medical research so SRX will never happen again. Opportunistic drug companies such as CEPH.NASDAQ now TEVA tried to take it over & failed, with a lowball bid,
Altho corporates like NEU, NAN & IPD will undoubtedly give higher SP trajectories if successful, they will not have SRX's trajectory as it got such a great Judgement in UWA v Gray, so IMHO not another SRX will occur with such a leg up, at least not in Aust while the IP laws & uni funding of medical research r as they r. GSK, Merck & AZN do a bit of funding but the mid/small caps like NEU, IPD, NAN, BIT etc all have harder roads with not as much initial backing from the likes of UWA (please see UWA v Gray Judgement), it's now much harder to commercialise from uni seed capital due to the UWA v Gray judgement IMHO but pls DYOR.
SRX Price at posting:
$28.47 Sentiment: Buy Disclosure: Held
